Sorry, you need to enable JavaScript to visit this website.

Lipids | INVEGA SUSTENNA® HCP
  1. Safety & Tolerability
  2. Lipids | INVEGA SUSTENNA® HCP

INVEGA SUSTENNA® Safety Profile: Lipids

Cholesterol

From 4 placebo-controlled, 9- to 13-week, fixed-dose studies1

A bar graph showing cholesterol on a fixed dose with INVEGA SUSTENNA®

LDL

From 4 placebo-controlled, 9- to 13-week, fixed-dose studies

A bar graph showing IDL on a fixed dose with INVEGA SUSTENNA®

HDL

From 4 placebo-controlled, 9- to 13-week, fixed-dose studies

A bar graph showing HDL on a fixed dose with INVEGA SUSTENNA®

Triglycerides

From 4 placebo-controlled, 9- to 13-week, fixed-dose studies

A bar graph showing triglycerides on a fixed dose with INVEGA SUSTENNA®

DYSLIPIDEMIA: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.1

Please see Important Safety Information.

*Initial deltoid injection of 234-mg followed by 39-mg, 156-mg, or 234-mg every 4 weeks by deltoid or gluteal injection. Other dose groups (39-mg, 78-mg, and 156-mg) are from studies involving only gluteal injection.

Study Design

Results from 4 placebo-controlled (one 9-week and three 13-week), fixed-dose studies of adult patients experiencing an acute exacerbation of schizophrenia.1

Reference: 1. INVEGA SUSTENNA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; July 2022.